<DOC>
	<DOC>NCT01514864</DOC>
	<brief_summary>The purpose of this study is to establish whether patients with malignancy harboring a discoidin domain receptor 2 mutation or an inactivating B-RAF mutation will respond to dasatinib.</brief_summary>
	<brief_title>Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Diagnosis of advanced malignancy, nonsmallcell lung cancer (NSCLC) only during stage 1 of accrual Nonsynonymous mutation of BRAF or DDR2, defined as follows: NSCLC with inactivating BRAF mutation NSCLC with discoidin domain receptor 2 (DDR2) mutation Malignancy of other histology with DDR2 mutation or inactivating BRAF mutation, or NSCLC having a BRAF mutation that is not functionally characterized At least 1 target lesion per Response Evaluation Criteria in Solid Tumors, vol 1.1, on baseline staging evaluation Disease progression after ≥ 1 prior treatment regimen Pleural or pericardial effusion, Grade &gt;1 QTcF &gt;470 msec (Grade ≥2) or diagnosed congenital long QT syndrome Absolute granulocyte count &lt;1500/mm^3 Hemoglobin level &lt;10 g/dL Platelet count &lt; 75,000/mm^3 Serum calcium level &lt;institutional lower limit of normal Hypokalemia, hypophosphatemia, or hypomagnesemia, Grade &gt;1, despite supplementation Creatinine &gt;3*institutional upper limit of normal (ULN) Total bilirubin level &gt;1.5*ULN Alanine transaminase level &gt;3*ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>